HOME >> BIOLOGY >> NEWS
Common cause of heart disease, diabetes may be treatable with malaria drug

Studies of a rare genetic condition that increases cancer risk have unveiled a potential treatment for metabolic syndrome, a common disorder that afflicts as many as one in every four American adults and puts them at sharply increased risk of type 2 diabetes and clogged arteries.

Scientists know relatively little about metabolic syndrome, which is linked to a range of symptoms that include obesity, insulin resistance, high blood pressure, low levels of good cholesterol and high blood sugar levels. The number of adults and children with the condition is rising sharply in industrial countries, and diagnoses are also increasing in developing countries like India and China as they adopt Western standards of living.

In findings published in the November issue of Cell Metabolism, researchers at Washington University School of Medicine in St. Louis and St. Jude Children's Research Hospital in Memphis, Tenn. report that a small dose of the malaria drug chloroquine eased many symptoms of metabolic syndrome in mice, reducing blood pressure, decreasing hardening and narrowing of the arteries and improving blood sugar tolerance.

"We just received funding for a clinical trial, and we're very excited to see if the processes activated by chloroquine can effectively treat one of the most common health problems of modern industrialized society," says senior author Clay F. Semenkovich, M.D., professor of medicine and of cell biology and physiology at Washington University. "We already know that chloroquine is safe and well-tolerated, and our mouse results suggest we may only need very low and perhaps infrequent doses to achieve similar effects in humans."

Researchers elsewhere proposed recently that high doses of the anti-aging molecule resveratrol might similarly treat obesity and metabolic syndrome. However, it is unclear if such high doses are safe, and scientists know relatively little about how resveratrol is easing symptoms.


'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
7-Nov-2006


Page: 1 2 3

Related biology news :

1. Common environmental chemicals in diet affect fetal ovarian development
2. Common cancer gene sends death order to tiny killer
3. Common treatment for methamphetamine overdose may damage brain cells
4. Common genetic variation is linked to substantial risk for heart attack
5. Common fungicide causes long-term changes in mating behavior
6. DNA ends: Common tool, different job
7. Common gene version optimizes thinking -- but with a possible downside
8. Common mechanisms for viral DNA replication
9. Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia
10. Commonplace sugar compound silences seizures
11. Common garden plant threatened by climate change

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/6/2019)... ... June 05, 2019 , ... MedTech Breakthrough , an ... and medical technology market, announced that it has selected Medacta International’s MySpine® MC ... in the 2019 MedTech Breakthrough Awards program. , Medacta® is ...
(Date:6/4/2019)... (PRWEB) , ... June 04, 2019 , ... ... manufacturing of orthopedic medical devices, today announced Q1-19 revenues of $31M, up 12% ... combined with successful roll-out of strategic investments & operational excellence initiatives worldwide. , ...
(Date:6/4/2019)... ... June 04, 2019 , ... Most preclinical EEG ... seizure risk signals, usually based on variations of amplitude, frequency or spike train ... diagnostic methodology due to the complexity and variability of the signal, and automation ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... , ... June 10, 2019 , ... ... and technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local ... Group) and will educate viewers about how its technology facilitates laboratories to improve ...
(Date:6/11/2019)... BETHESDA, Md. and ROANOKE, Va. (PRWEB) , ... ... ... virtual care optimized for microlearning engagement, and Carilion Clinic, a national leader in ... leveraging the latest in virtual care. , Mytonomy recently deployed its ...
(Date:6/11/2019)... ... June 11, 2019 , ... A ... mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying ... on mice, MSC-EVs also increased the cells’ ability to lodge into bone marrow. ...
(Date:5/31/2019)... ... 2019 , ... For many years, the primary forms of cancer treatment have ... Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR ... receptors known as “CARs”. The CAR enables the final product to produce chemicals in ...
Breaking Biology Technology:
Cached News: